We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+8.51%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$342M
AUM Growth
+$89.9M
Cap. Flow
+$78.3M
Cap. Flow %
22.9%
Top 10 Hldgs %
35.24%
Holding
113
New
44
Increased
16
Reduced
11
Closed
37

Top Buys

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$9.51M
2
DXCM icon
DexCom
DXCM
+$8.48M
3
AGN
Allergan plc
AGN
+$8.14M
4
CNC icon
Centene
CNC
+$6.89M
5
INCY icon
Incyte
INCY
+$6.33M

Top Sells

Rank Stock Value
1
LH icon
Labcorp
LH
+$10M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$8.72M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$6.55M
4
NXTM
NxStage Medical Inc.
NXTM
+$5.56M
5
QGENF
QIAGEN NV
QGENF
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 49.95%
2 Industrials 2.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
26
QuidelOrtho
QDEL
$838M
$4.83M 1.41%
+110,000
New +$3.83M
VRTX icon
27
Vertex Pharmaceuticals
VRTX
$126B
$4.55M 1.33%
+29,900
New +$4.5M
NSTG
28
DELISTED
NanoString Technologies, Inc.
NSTG
$4.44M 1.3%
275,000
-123,206
-31% -$1.9M
AXGN icon
29
Axogen
AXGN
$2.5B
$4.44M 1.3%
229,278
+49,909
+28% +$839K
XBI icon
30
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$4.33M 1.27%
+50,000
New +$4.01M
ABT icon
31
Abbott
ABT
$187B
$4.27M 1.25%
+80,000
New +$4.01M
ADMS
32
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
$4.23M 1.24%
+200,000
New +$3.67M
ISRG icon
33
CALL
Intuitive Surgical
ISRG
$134B
$4.18M 1.22%
36,000
-9,000
-20% -$981K
ABT icon
34
CALL
Abbott
ABT
$187B
$4M 1.17%
+75,000
New +$3.76M
GMED icon
35
Globus Medical
GMED
$11.2B
$3.84M 1.12%
129,074
-70,926
-35% -$2.17M
EW icon
36
CALL
Edwards Lifesciences
EW
$51.7B
$3.83M 1.12%
105,000
+15,000
+17% +$572K
VRAY
37
DELISTED
ViewRay, Inc.
VRAY
$3.5M 1.02%
607,040
+346,370
+133% +$1.95M
NBRV
38
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.48M 1.02%
+1,700
New +$3.99M
PRAH
39
DELISTED
PRA Health Sciences, Inc.
PRAH
$3.43M 1%
45,000
-27,500
-38% -$2.08M
FXH icon
40
PUT
First Trust Health Care AlphaDEX Fund
FXH
$1.11B
$3.37M 0.99%
+50,000
New +$3.34M
ALXN
41
DELISTED
Alexion Pharmaceuticals
ALXN
$3.35M 0.98%
23,900
-64,212
-73% -$8.72M
ONCE
42
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$3.35M 0.98%
+37,589
New +$2.85M
IBB icon
43
PUT
iShares Biotechnology ETF
IBB
$9.71B
$3.34M 0.98%
+30,000
New +$3.21M
FPRX
44
CALL
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.07M 0.9%
+75,000
New +$2.35M
FOLD
45
CALL
DELISTED
Amicus Therapeutics
FOLD
$3.02M 0.88%
+200,000
New +$2.65M
PBYI icon
46
CALL
Puma Biotechnology
PBYI
$454M
$2.99M 0.88%
+25,000
New +$2.33M
SIEN
47
DELISTED
Sientra, Inc.
SIEN
$2.89M 0.85%
+18,780
New +$2.2M
AZTA icon
48
Azenta
AZTA
$1.48B
$2.88M 0.84%
+95,000
New +$2.44M
ARNA
49
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.85M 0.83%
111,700
+76,700
+219% +$1.76M
INSM icon
50
Insmed
INSM
$28.6B
$2.73M 0.8%
+87,601
New +$1.67M
1
2
3 4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
ONGA
O'Neil Global Advisors Los Angeles, California $14.4M AUM 220.73% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM

Pura Vida Investments's Q3 2017 Portfolio in Review

As of Q3 2017, Pura Vida Investments held 113 positions worth $342M, up 36% from $252M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Pura Vida Investments deployed $78.3M of net new capital in Q3 2017, opening 44 new positions and adding to 16 existing holdings. Its largest new stake was Dentsply Sirona: 160,000 shares worth $9.57M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 66% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $8.72M trimmed.

  • Pura Vida Investments's largest Q3 2017 buy was Dentsply Sirona: 160,000 shares worth $9.57M.
  • Pura Vida Investments added most to Athenahealth, Inc. in Q3 2017, an estimated $2.31M increase.
  • Pura Vida Investments's biggest Q3 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $8.72M.
  • Pura Vida Investments fully exited Labcorp in Q3 2017, selling an estimated $10M.
  • Pura Vida Investments's ten largest holdings make up 35% of its $342M portfolio in Q3 2017.
  • Pura Vida Investments opened 44 new positions and closed 37 in Q3 2017.
  • Pura Vida Investments's portfolio value rose 36% quarter-over-quarter to $342M.

Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.